ReviewNeurology international2023
Leukoaraiosis as a Predictor of Depression and Cognitive Impairment among Stroke Survivors: A Systematic Review.
Review in Neurology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Mechanisms and biomarkers of poststroke cognitive impairment.Neural regeneration research · 2026Article
- A nomogram model for identifying cognitive frailty in elderly patients with chronic diseases: a multicenter cross-sectional study.Frontiers in public health · 2026Observational
- Neuroprotective Effect of Rosuvastatin Calcium Combined with Hyperbaric Oxygen Mediated p38MAPK Pathway in Rats with Leukoaraiosis.Cell biochemistry and biophysics · 2025Article
- Myelin basic protein and occludin may be the biomarkers to diagnose leukoaraiosis and cognitive dysfunction.Scientific reports · 2025Article
- Dialysis and cognitive impairment.Nature reviews. Nephrology · 2025Review
- A Scoping Review on Cognition in Myelodysplastic Syndromes: Advances and Challenges.Medical sciences (Basel, Switzerland) · 2025Article
- Blood biomarkers for vascular cognitive impairment based on neuronal function: a systematic review and meta-analysis.Frontiers in neurology · 2025Review
- Predictive Markers of Post-Stroke Cognitive Recovery and Depression in Ischemic Stroke Patients: A 6-Month Longitudinal Study.European journal of investigation in health, psychology and education · 2024Article
- Dementia after Ischemic Stroke, from Molecular Biomarkers to Therapeutic Options.International journal of molecular sciences · 2024Review
- Risk factors and a nomogram for predicting cognitive frailty in Chinese patients with lung cancer receiving drug therapy: A single-center cross-sectional study.Thoracic cancer · 2024Article
- Brain frailty associated with stroke events in anterior circulation large artery occlusion.BMC neurology · 2024Article
- A Comprehensive Review on the Role of Resting-State Functional Magnetic Resonance Imaging in Predicting Post-Stroke Motor and Sensory Outcomes.Neurology international · 2024Review
- Leukoaraiosis as a Promising Biomarker of Stroke Recurrence among Stroke Survivors: A Systematic Review.Neurology international · 2023Review
- Larger deep white matter hyperintensity volume correlates with more severe social behavioral changes in patients with subacute ischemic stroke.Frontiers in aging neuroscience · 2023Article
- Mechanisms associated with post-stroke depression and pharmacologic therapy.Frontiers in neurology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
Abstract
Stroke survivors are at increased risk of developing depression and cognitive decline. Thus, it is crucial for both clinicians and stroke survivors to be provided with timely and accurate prognostication of post-stroke depression (PSD) and post-stroke dementia (PSDem). Several biomarkers regarding stroke patients' propensity to develop PSD and PSDem have been implemented so far, leukoaraiosis (LA) being among them. The purpose of the present study was to review all available work published within the last decade dealing with pre-existing LA as a predictor of depression (PSD) and cognitive dysfunction (cognitive impairment or PSDem) in stroke patients. A literature search of two databases (MEDLINE and Scopus) was conducted to identify all relevant studies published between 1 January 2012 and 25 June 2022 that dealt with the clinical utility of preexisting LA as a prognostic indicator of PSD and PSDem/cognitive impairment. Only full-text articles published in the English language were included. Thirty-four articles were traced and are included in the present review. LA burden, serving as a surrogate marker of "brain frailty" among stroke patients, appears to be able to offer significant information about the possibility of developing PSD or cognitive dysfunction. Determining the extent of pre-existing white matter abnormalities can properly guide decision making in acute stroke settings, as a greater degree of such lesioning is usually coupled with neuropsychiatric aftermaths, such as PSD and PSDem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.